Opening up to precompetitive collaboration

Science Translational Medicine

Volumn 2, Issue 52, 2010, Pages

  Altshuler, Jill S ^a   Balogh, Erin ^b   Barker, Anna D ^c   Eck, Stephen L ^d   Friend, Stephen H ^e   Ginsburg, Geoffrey S ^f   Herbst, Roy S ^g   Nass, Sharyl J ^b   Streeter, Christopher M ^a   Wagner, John A ^h  

^a AltshulerGray   (United States)

^b INSTITUTE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e SAGE BIONETWORKS   (United States)

^f DUKE UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICINE; CANCER RESEARCH; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; KNOWLEDGE; MEDICAL INFORMATION; MEDICAL RESEARCH; NOTE; ONCOLOGY; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SOCIAL MARKETING; STANDARDIZATION; ARTICLE; COOPERATION; ECONOMICS; HUMAN; METHODOLOGY; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; TRANSLATIONAL RESEARCH;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; HUMANS; MODELS, ORGANIZATIONAL; PATENTS AS TOPIC; TRANSLATIONAL RESEARCH;

EID: 77958102216     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001515     Document Type: Note

References (25)

1. E. R. Dorsey, J. de Roulet, J. P. Thompson, J. I. Reminick, A. Thai, Z. White-Stellato, C. A. Beck, B. P. George, H. Moses 3rd, Funding of US biomedical research, 2003-2008. J. Am. Med. Assoc. 303, 137-143 (2010).
2. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
3. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
4. T. Melese, S. M. Lin, J. L. Chang, N. H. Cohen, Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nat. Med. 15, 502-507 (2009).
5. President's Council of Advisors on Science and Technology, University-Private Sector Research Partnerships in the Innovation Ecosystem (2008): www.nasa.gov/ pdf/404101main-past-research-partnership-report-BOOK.pdf.
6. C. Nathan, Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304-308 (2007).
7. A. K. Rai, Open and collaborative research: A new model for biomedicine? In Intellectual Property Rights in Frontier Industries: Software and Biotech, Robert Hahn, Ed. (AEI-Brookings Press, Washington, DC, 2005). http:// scholarship.law.duke.edu/faculty-scholarship/882.
8. A. D. Barker, C. C. Sigman, G. J. Kelloff, N. M. Hylton, D. A. Berry, L. J. Esserman, I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).
9. Sage Bionetworks: www.sagebase.org/.
10. B. Munos, Can open-source R&D reinvigorate drug research? Nat. Rev. Drug Discov. 5, 723-729 (2006).
11. M. R. Barnes, L. Harland, S. M. Foord, M. D. Hall, I. Dix, S. Thomas, B. I. Williams-Jones, C. R. Brouwer, Lowering industry firewalls: Pre-competitive informatics initiatives in drug discovery. Nat. Rev. Drug Discov. 8, 701-708 (2009).
12. And the winner is... Capturing the promise of philanthropic prizes (McKinsey & Company, Sydney, 2009); www.mckinsey.com/App-Media/Reports/SSO/ And-the-winner-is.pdf.
13. J. Travis, Research funding: Prizes eyed to spur medical innovation. Science 319, 713 (2008).
14. J. Travis, Science and commerce: Science by the masses. Science 319, 1750-1752 (2008).
15. R. Fuchs, personal communication. See www.biogenidec. com/bi3/.
16. AstraZeneca and Merck & Co., Inc. form pioneering collaboration to investigate novel combination anticancer regimen. (press release, 2009); www.merck. com/newsroom/news-release-archive/research-and-development/ 2009-0601.html.
17. M. Herper, Patient Power. Forbes (15 September 2008); www.forbes.com/forbes/2008/0915/070-print.html.
18. J. Groopman, "Buying a cure: What business know-how can do for disease," The New Yorker (28 January 2008); www.newyorker.com/reporting/ 2008/01/28/080128fa- fact-groopman?printable=true.
19. S. M. Maurer, A. Rai, A. Sali, Finding cures for tropical diseases: Is open source an answer? PLoS Med. 1, e56 (2004).
20. "An open-source shot in the arm?" The Economist (10 June 2004); www.economist.com/PrinterFriendly.cfm? Story-ID=2724420.
21. S. M. Maurer, Choosing the right incentive strategy for research and development in neglected diseases. Bull. World Health Organ. 84, 376-381 (2006).
22. C. Christensen, R. Bohmer, J. Kenegy, "Will disruptive innovations cure health care?" Harvard Business Review (September-October 2000); http://hbr.org/hbr-main/ resources/pdfs/comm/philips/disruptive-innovationscure- health.pdf.
23. B. H. Munos, W. W. Chin, A call for sharing: Adapting pharmaceutical research to new realities. Sci. Transl. Med. 1, cm8 (2009).
24. S. Friend, Crowdsourcing drug discovery, The Scientist, 24, 32 (2010).
25. J. A. Wagner, M. Prince, E. C. Wright, M. M. Ennis, J. Kochan, D. J. Nunez, B. Schneider, M. D. Wang, Y. Chen, S. Ghosh, B. J. Musser, M. T. Vassileva, The Biomarkers Consortium: Practice and pitfalls of open-source precompetitive collaboration. Clin. Pharmacol. Ther. 87, 539-542 (2010).